Drug Trial Radar · NCT05362058
A Study of Insulin Efsitora Alfa (LY3209590) Compared to Degludec in Adults With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time
Last checked: Nov 20, 2026Latest source record: May 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
928
Actual
Start
Jun 3, 2022
Primary completion
Apr 10, 2024
Study completion Apr 10, 2024
Sponsor
- Lead sponsor
- Eli Lilly and CompanyEli Lilly (LLY)
- Sponsor type
- Industry
- First posted
- May 5, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine the effect and safety of insulin efsitora alfa (LY3209590) compared to degludec in adult participants with type 2 diabetes who are starting basal insulin for the first time. The study consists of a 1-week screening period, a 2-week lead-in period, a 52-week treatment period, and a 5-week safety follow-up period. The study will last up to 60 weeks.
Conditions
- Diabetes
- Type 2 Diabetes
Interventions
Insulin Efsitora AlfaDrug
Administered SC
Insulin DegludecDrug
Administered SC
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in HbA1c at Week 52 [Noninferiority Analysis]Time frame: Baseline, Week 52
Locations
113 sites in 11 countries. Site status is shown where the registry gives one.
Neighborhood Healthcare Institute of Health
Escondido, California
Valley Research
Fresno, California
NorCal Medical Research, Inc
Greenbrae, California
Catalina Research Institute, LLC
Montclair, California
Southern California Dermatology, Inc.
Santa Ana, California
New West Physicians Clinical Research
Golden, Colorado
New England Research Associates, LLC
Bridgeport, Connecticut
East Coast Institute for Research, LLC
Jacksonville, Florida
East Coast Institute for Research - Canton
Canton, Georgia
Rophe Adult and Pediatric Medicine/SKYCRNG
Union City, Georgia
Central Illinois Diabetes and Clinical Research a Division of Prairie Education and Research Cooperative
Springfield, Illinois
Qualmedica Research, LLC
Evansville, Indiana
Iowa Diabetes and Endocrinology Research Center
West Des Moines, Iowa
Qualmedica Research
Bowling Green, Kentucky
MedStar Health Research Institute (MedStar Physician Based Research Network)
Hyattsville, Maryland
Endocrine and Metabolic Consultants
Rockville, Maryland
SKY Clinical Research Network Group-Quinn
Ridgeland, Mississippi
Clinvest Research LLC
Springfield, Missouri
Clarity Clinical Research
East Syracuse, New York
Great Lakes Medical Research, LLC
Westfield, New York
Monroe Biomedical Research
Monroe, North Carolina
Lucas Research, Inc
Morehead City, North Carolina
Intend Research, LLC
Norman, Oklahoma
Jefferson Clinical Research Institute (JCRI)
Philadelphia, Pennsylvania
Tribe Clinical Research, LLC
Greenville, South Carolina
Dallas Diabetes Research Center
Dallas, Texas
Juno Research
Houston, Texas
Southern Endocrinology Associates
Mesquite, Texas
North Hills Family Medicine/North Hills Medical Research
North Richland Hills, Texas
Multicare Institute for Research and Innovation
Spokane, Washington
Hospital São Lucas de Copacabana
Rio de Janeiro, Brazil
CPQuali Pesquisa Clínica
São Paulo, Brazil
CPCLIN
São Paulo, Brazil
CEPIC - Centro Paulista de Investigação Clínica
São Paulo, Brazil
CEDOES
Vitória, Espírito Santo, Brazil
Cline Research Center
Curitiba, Paraná, Brazil
Centro de Pesquisa Sao Lucas
Campinas, São Paulo, Brazil
LMC Diabetes & Endocrinology
Brampton, Ontario, Canada
Aggarwal and Associates Limited
Brampton, Ontario, Canada
LMC Manna Research
Ottawa, Ontario, Canada
Showing 40 of 113 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.